Business
Ventripoint's VMS+ Purchased by Medical Center - University of Freiburg
(TheNewswire) Toronto, Ontario – The Newswire – July 18, 2023 - Ventripoi...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint's VMS+ Purchased by Medical Center - University of Freiburg\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario – The Newswire –\nJuly 18, 2023\n \n \n - Ventripoint Diagnostics Ltd.\n(\"\n \n \n Ventripoint\n \n \n \" or the \"\n \n \n Company\n \n \n \"), (TSXV:VPT\n \n \n )\n \n \n (\n \n \n OTC:VPTDF)\n \n \n is pleased to announce that Freiburg Hospital\nhas chosen to adopt the VMS+ as its cardiac diagnostic tool.\n \n \n \n \n The University Medical Centre Freiburg im Breisgau,\nGermany, is notably one of the largest hospitals in Europe and is\nrecognized as the supra-regional centre for the treatment of\ncomplicated heart disease.\n \n \n It treats\n \n \n approximately 90,000\n \n \n \n inpatients and\n897,000 outpatients annually.\n \n \n \n \n \n \n Dr. Alvira Macanovic, Ventripoint’s President and CEO\nstated,\n \n \n \n “This year the Ventripoint\nteam is laser-focused on sales growth and this sale to a leading\ninstitution in Europe is indicative of the sales momentum and traction\nwe are seeing in one of our key markets through the cooperative\nefforts of our direct sales team, channel partners, and trial teams.\n \n \n \n \n The VMS+ will be utilized by the department of\ncongenital heart defects and paediatric cardiology who treat 4,000+\nchildren, youth, and young adults with congenital and acquired heart\ndiseases each year. With the VMS+, the cardiac medical centre will be\nable to make its diagnostic and procedural decisions more efficiently\nand quickly, leading to better outcomes for patients. The VMS+ will\nserve as an adjunct to speed up decision-making in patient treatment\nand as an alternative to cardiac MRI when a patient is\ncontraindicated.  Most importantly, VMS+ will be used to aid in\ndiagnosis and in continuous monitoring of patients throughout their\njourney as performing a VMS+ study fits normal scanning workflows.\n The VMS+ will also be used to assist in the research of terminal\nheart failure and mechanical cardiovascular replacement and in\npediatric drug trials for congenital heart defects.\n \n \n \n \n Sales, installation and support of the VMS+ in Europe\nis handled by Angiopro GmbH. The cooperation between Ventripoint and\nAngiopro ensures optimal customer service, so that all VM...